Advertisement

Research Article Free access | 10.1172/JCI118333

Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1.

T A McCaffrey, S Consigli, B Du, D J Falcone, T A Sanborn, A M Spokojny, and H L Bush Jr

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by McCaffrey, T. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Consigli, S. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Du, B. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Falcone, D. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Sanborn, T. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Spokojny, A. in: PubMed | Google Scholar

Department of Medicine, Division of Hematology/Oncology, Cornell University Medical College, New York Hospital, New York 10021, USA.

Find articles by Bush, H. in: PubMed | Google Scholar

Published December 1, 1995 - More info

Published in Volume 96, Issue 6 on December 1, 1995
J Clin Invest. 1995;96(6):2667–2675. https://doi.org/10.1172/JCI118333.
© 1995 The American Society for Clinical Investigation
Published December 1, 1995 - Version history
View PDF
Abstract

Atherosclerosis and postangioplasty restenosis may result from abnormal wound healing. The present studies report that normal human smooth muscle cells are growth inhibited by TGF-beta1, a potent wound healing agent, and show little induction of collagen synthesis to TGF-beta1, yet cells grown from human vascular lesions are growth stimulated by TGF-beta1 and markedly increase collagen synthesis. Both cell types increase plasminogen activator inhibitor-1 production, switch actin phenotypes in response to TGF-beta1, and produce similar levels of TGF-beta activity. Membrane cross-linking of 125I-TGF-beta1 indicates that normal human smooth muscle cells express type I, II, and III receptors. The type II receptor is strikingly decreased in lesion cells, with little change in the type I or III receptors. RT-PCR confirmed that the type II TGF-beta1 receptor mRNA is reduced in lesion cells. Transfection of the type II receptor into lesion cells restores the growth inhibitory response to TGF-beta1, implying that signaling remains responsive. Because TGF-beta1 is overexpressed in fibroproliferative vascular lesions, receptor-variant cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components. This TGF-beta1 receptor dysfunction may be relevant for atherosclerosis, restenosis and related fibroproliferative diseases.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (December 1, 1995): No description
Advertisement
Advertisement